Moleculin Announces Significant Discovery in Lung Cancer Models

HOUSTON. Tx. – Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, announced that i...

Aprea Therapeutics Receives FDA Fast Track Designation and Orphan Drug Designation for APR-246 for the Treatment of Myelodysplastic Syndromes (MDS)

BOSTON, MA. and STOCKHOLM, SWEDEN– Aprea Therapeutics, a privately held, clinical stage biopharmaceutical company developing novel anticancer therapies targeting the tumor suppressor protein p53, tannounced that the U.S....

Molmed Receives Green Light for Phase 1/2 Trial to Test CAR T-Cell Therapy in Myeloma, Leukemia Patients

The Italian Medicines Agency has approved a first-in-human clinical trial testing MolMed's investigational CAR T-cell product, CD44v6, for the treatment of acute myeloid leukemia and multiple myeloma, the company announc...

Biologics License Application Accepted for Brolucizumab for Wet AMD

The FDA has accepted a biologics license application forbrolucizumab for the treatment of neovascular age-related macular degeneration, Novartis announced in a press release.The application was based on phase 3 data from...

Avexis Data Reinforce Effectiveness of Zolgensma(R) in Treating Spinal Muscular Atrophy (SMA) Type 1

Basel, Switzerland  - AveXis, a Novartis company,  announced that interim data from its Phase 3 STR1VE trial of Zolgensma® (onasemnogene abeparvovec-xioi; AVXS-101)[1] in spinal muscular atrophy (SMA) Type 1 showed prolo...

Agilent Receives an Expanded FDA Approval for its Companion Diagnostic in NSCLC

SANTA CLARA, California--Agilent Technologies Inc. announced that the U.S. Food and Drug Administration has updated its approval of the company's PD-L1 IHC 22C3 pharmDx assay.The assay can now be used as a companion diag...

Santhera to Present Long-term Efficacy Results with Idebenone in DMD at the 2019 MDA Clinical and Scientific Conference

PRATTELN, Switzerland - Santhera Pharmaceuticals (SIX: SANN) and its collaborating clinical experts present results of long-term efficacy on respiratory function outcomes in idebenone-treated patients with Duchenne muscu...

Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study

CAMBRIDGE, Mass.- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced that the Company has initiated ILLUMINATE-B, a global Phase 3 pediatric study of lumasiran, an investigation...

CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Beta Thalassemia

ZUG, Switzerland and CAMBRIDGE and BOSTON, Mass.- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX)  announced that the U.S. Food and Drug Administration (FDA) has granted Fast Tra...

aTyr Pharma to Host Inaugural Summit Meeting on Neuropilin-2 (NRP-2) Biology

SAN DIEGO- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, announced that the Company will host a summit...